Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 6/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5738819 | 0.89 | KMT2A (0.62) | HTTALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL28613032 | 0.82 | ALDH1A1 (0.60) | HTTALDH1A1TSHRKMT2AHPGD | |
| SCHEMBL3531624 | 0.82 | HTT (0.60) | HTTALDH1A1KMT2APOLBHPGD | |
| SCHEMBL3888217 | 0.82 | HTT (0.51) | HTTALDH1A1TSHRKMT2APOLB | |
| SCHEMBL14618673 | 0.82 | HTT (0.51) | HTTALDH1A1TSHRKMT2APOLB | |
| SCHEMBL3535128 | 0.82 | HTT (0.60) | HTTALDH1A1KMT2APOLBHPGD | |
| SCHEMBL14714286 | 0.81 | ALDH1A1 (0.44) | HTTALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL9826058 | 0.80 | ALDH1A1 (0.58) | HTTALDH1A1TSHRKMT2AHPGD | |
| SCHEMBL31628174 | 0.80 | ALDH1A1 (0.58) | HTTALDH1A1TSHRKMT2AHPGD | |
| SCHEMBL27716526 | 0.79 | HTT (0.58) | HTTALDH1A1KMT2APOLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787535-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; PARKINSON'S DISEASE, HUNTINGTON'S DISEASE; PSYCOLOGICAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-09-07 | — | — | US | claimed |
| US-20030073700-A1 | New indole derivatives with 5HT6 receptor affinity | SYNTEX (U.S.A.) LLC, NAME CHANGE TO ROCHE PALO ALTO LLC | 2003-04-17 | — | — | US | claimed |
| US-8252841-B2 | Methods of inhibiting bacterial virulence and compounds relating thereto | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-08-28 | — | — | US | disclosed |
| US-7589108-B2 | 1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589108-B2 | 1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-09-15 | — | — | US | disclosed |
| US-20090012308-A1 | PROCESS FOR THE MANUFACTURE OF BENZYLSULFONYLARENES | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
| US-20060030593-A1 | 1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-02-09 | — | — | US | disclosed |
| US-6995176-B2 | 1-heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050171118-A1 | New indole derivatives with 5-HT6 receptor affinity | BEARD COLIN C (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1554244-A1 | 1-HETEROCYCLYLALKYL-3-SULFONYLINDOLE OR -INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2005-07-20 | — | — | EP | disclosed |
| US-20040248902-A1 | New indole derivatives with 5-HT6 receptor affinity | BEARD COLIN CHARLES (US) | 2004-12-09 | — | — | US | disclosed |
| US-6787535-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; PARKINSON'S DISEASE, HUNTINGTON'S DISEASE; PSYCOLOGICAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-09-07 | — | — | US | disclosed |
| US-20040024023-A1 | 1-Heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-02-05 | — | — | US | disclosed |
| WO-2004009548-A1 | 1-HETEROCYCLYLALKYL-3-SULFONYLINDOLE OR -INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2004-01-29 | — | — | WO | disclosed |
| US-20030073700-A1 | New indole derivatives with 5HT6 receptor affinity | SYNTEX (U.S.A.) LLC, NAME CHANGE TO ROCHE PALO ALTO LLC | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030593-A1 | 1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3A, HTR5A | HTT 364/4885ALDH1A1 819/4885TSHR 229/4885 |
| US-20040248902-A1 | New indole derivatives with 5-HT6 receptor affinity | HTR6, HTR5A, HTR7 | HTT 1358/4885ALDH1A1 1833/4885TSHR 182/4885 |
| US-20050171118-A1 | New indole derivatives with 5-HT6 receptor affinity | HTR6, HTR5A, HTR7 | HTT 1087/4885ALDH1A1 2354/4885TSHR 137/4885 |
| US-20090012308-A1 | PROCESS FOR THE MANUFACTURE OF BENZYLSULFONYLARENES | HTR6, HTR2B, HTR3B | HTT 285/4885ALDH1A1 721/4885TSHR 121/4885 |
| US-20030073700-A1 | New indole derivatives with 5HT6 receptor affinity | HTR6, HTR5A, HTR7 | HTT 1221/4885ALDH1A1 1394/4885TSHR 176/4885 |
| US-20040024023-A1 | 1-Heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3A, HTR1A | HTT 389/4885ALDH1A1 894/4885TSHR 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.